<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950544</url>
  </required_header>
  <id_info>
    <org_study_id>STPH-ICU-002</org_study_id>
    <nct_id>NCT03950544</nct_id>
  </id_info>
  <brief_title>The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae</brief_title>
  <official_title>How to Optimize the Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The infection of carbapenem resistant klebsiella pneumoniae (CRKP) is increasingly
      serious.Based on the early experimental basis and relevant research background,this study
      intends to separate and purify the CRKP from the bronchoalveolar lavage fluid (BALF) of the
      clinical patients.Designed by checkerboard assay and time-kill assay(TKA)，this study can
      explore the best combination therapy based on carbapenems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Collect the BALF from patients diagnosed with CRKP infection in surgical intensive care
           unit（SICU）of Shanghai 10th people's hospital.

        2. Separate and purify the BALF. Divide each CRKP into four treatment groups based on
           meropenem.

      3.1 By checkerboard method and microdilution broth method,get the minimal inhibitory
      concentration (MICS) of two antibiotics,then calculate the fractional inhibitory
      concentration (FIC) index according to MIC results.

      3.2 Observe the effect of two antibiotics on the growth of CRKP by TKA.

      4.By the above two invitro experiments, analyze the data of the experimental results and get
      the best combination therapy based on carbapenems.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the fractional inhibitory concentration index (FICI)</measure>
    <time_frame>24hours-36hours</time_frame>
    <description>By checkerboard method and microdilution broth method,get the minimal inhibitory concentration (MICS) of two antibiotics,then calculate the fractional inhibitory concentration (FIC) index according to MIC results.
Evaluation index:
FIC=0.5 , coordinating effect. 0.5 &lt; FIC &lt;1, adding effect;
1 &lt; FIC &lt;2, irrelevant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the time-kill assay (TKA)</measure>
    <time_frame>36hours-48hours</time_frame>
    <description>According to the Clinical and Laboratory Standards Institute,observe the changes of bacterial growth over time after different combination therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Antibiotic Resistant Infection</condition>
  <arm_group>
    <arm_group_label>only meropenem therapy,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this group is only meropenem therapy as a single antibiotic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin</intervention_name>
    <description>Fosfomycin and meropenem</description>
    <arm_group_label>only meropenem therapy,</arm_group_label>
    <other_name>meropenem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tigecycline</intervention_name>
    <description>Tigecycline and meropenem</description>
    <arm_group_label>only meropenem therapy,</arm_group_label>
    <other_name>meropenem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polymyxin B</intervention_name>
    <description>Polymyxin B and meropenem</description>
    <arm_group_label>only meropenem therapy,</arm_group_label>
    <other_name>meropenem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age from 18 to 90.

          -  infected with CRKP firstly .

        Exclusion Criteria:

          -  APACHE II score &gt; 35

          -  Vital signs are unstable

          -  Unable to tolerate fiberoptic bronchoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Hua, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai 10th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ma Lao, master</last_name>
    <phone>8613532437896</phone>
    <email>13532437896@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai 10th people's hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huanlong Qin, director</last_name>
      <phone>18917683138</phone>
      <email>wangsheng@tongji.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 11, 2019</last_update_submitted>
  <last_update_submitted_qc>May 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Sheng Wang MD PhD</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
    <mesh_term>Tigecycline</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

